HIV1 p55+p24+p17,艾滋病病毒抗体-抗体-抗体-生物在线
上海沪震实业有限公司
HIV1 p55+p24+p17,艾滋病病毒抗体

HIV1 p55+p24+p17,艾滋病病毒抗体

商家询价

产品名称: HIV1 p55+p24+p17,艾滋病病毒抗体

英文名称: Anti-HIV1 p55+p24+p17 antibody

产品编号: HZ-4942R

产品价格: null

产品产地: 中国/美国

品牌商标: HZbscience

更新时间: 2023-08-17T10:24:20

使用范围: WB,ELISA,IHC-P,IHC-F,IF

上海沪震实业有限公司
  • 联系人 : 鲍丽雯
  • 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
  • 邮编 : 200612
  • 所在区域 : 上海
  • 电话 : 139****0749 点击查看
  • 传真 : 点击查看
  • 邮箱 : www.shzbio.net
  • 二维码 : 点击查看

HIV1 p55+p24+p17,艾滋病病毒抗体

产品编号HZ-4942R
英文名称HIV1 p55+p24+p17
中文名称艾滋病病毒抗体
别 名HIV p55+Capsid protein p24; HIV1 p55 + p24 + p17; CA antibody Capsid protein p24; Gag; Gag polyprotein; HIV1 matrix protein p17; HIV1 Pr55Gag; Human immunodeficiency virus 1 p17; Human immunodeficiency virus 1 p55; Human immunodeficiency virus type 1 p24; MA antibody Matrix protein; Matrix protein p17; Pr55; Pr55Gag; POL_HV1H2.
说 明 书0.1ml 0.2ml
研究领域免疫学 细菌及病毒
抗体来源Rabbit
克隆类型Polyclonal
交叉反应 HIV
HIV1 p55+p24+p17,艾滋病病毒抗体产品应用WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蜡切片需做抗原修复)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量17/24/55/162kDa
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthetic peptide derived from HIV1 p55+p24+p17
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
HIV1 p55+p24+p17,艾滋病病毒抗体PubMedPubMed
产品介绍background:
HIV1 performs highly complex orchestrated tasks during the assembly, budding, maturation and infection stages of the viral replication cycle. During viral assembly, the proteins form membrane associations and self-associations that ultimately result in budding of an immature virion from the infected cell. Gag precursors also function during viral assembly to selectively bind and package two plus strands of genomic RNA. p55 is digested by HIV1 protease into intermediate products p41 and p15. p41 is further digested into matrix protein p17 and capsid protein p24. Likewise, p15 is further digested into nucleocapsid protein p7 and to p6 and p1.

Function:
Gag-Pol polyprotein and Gag polyprotein may regulate their own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, Gag-Pol and Gag would promote translation, whereas at high concentration, the polyproteins encapsidate genomic RNA and then shutt off translation.
Matrix protein p17 has two main functions: in infected cell, it targets Gag and Gag-pol polyproteins to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. The second function is to play a role in nuclear localization of the viral genome at the very start of cell infection. Matrix protein is the part of the pre-integration complex. It binds in the cytoplasm the human BAF protein which prevent autointegration of the viral genome, and might be included in virions at the ration of zero to 3 BAF dimer per virion. The myristoylation signal and the NLS thus exert conflicting influences its subcellular localization. The key regulation of these motifs might be phosphorylation of a portion of MA molecules on the C-terminal tyrosine at the time of virus maturation, by virion-associated cellular tyrosine kinase. Implicated in the release from host cell mediated by Vpu.
Capsid protein p24 forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry. Interaction with human PPIA/CYPA protects the virus from restriction by human TRIM5-alpha and from an unknown antiviral activity in human cells. This capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species.
Nucleocapsid protein p7 encapsulates and protects viral dimeric unspliced (genomic) RNA. Binds these RNAs through its zinc fingers. Facilitates rearangement of nucleic acid secondary structure during retrotranscription of genomic RNA. This capability is referred to as nucleic acid chaperone activity.

HIV1 p55+p24+p17,艾滋病病毒抗体Subunit:
Pre-integration complex interacts with human HMGA1. Matrix protein p17 is a trimer. Interacts with gp120 and human BAF. Capsid is a homodimer. Interacts with human PPIA/CYPA. The protease is a homodimer, whose active site consists of two apposed aspartic acid residues. The reverse transcriptase is a heterodimer of p66 RT and p51 RT (RT p66/p51). Heterodimerization of RT is essential for DNA polymerase activity. Despite the sequence identities, p66 RT and p51 RT have distinct folding. Integrase is a homodimer and possibly can form homotetramer. Integrase interacts with human SMARCB1/INI1 and human PSIP1/LEDGF isoform 1. Integrase interacts with human KPNA3; this interaction might play a role in nuclear import of the pre-integration complex. Integrase interacts with human NUP153; this interaction might play a role in nuclear import of the pre-integration complex (By similarity).

Subcellular Location:
Matrix protein p17: Virion (Potential). Host nucleus. Host cytoplasm. Host cell membrane; Lipid-anchor (Potential). Note=Following virus entry, the nuclear localization signal (NLS) of the matrix protein participates with Vpr to the nuclear localization of the viral genome. During virus production, the nuclear export activity of the matrix protein counteracts the NLS to maintain the Gag and Gag-Pol polyproteins in the cytoplasm, thereby directing unspliced RNA to the plasma membrane (By similarity).
Capsid protein p24: Virion (Potential).
Nucleocapsid protein p7: Virion (Potential).
Reverse transcriptase/ribonuclease H: Virion (Potential).
Integrase: Virion (Potential). Host nucleus (Potential). Host cytoplasm (Potential). Note=Nuclear at initial phase, cytoplasmic at assembly (Potential).

Post-translational modifications:
Specific enzymatic cleavages by the viral protease yield mature proteins. The protease is released by autocatalytic cleavage. The polyprotein is cleaved during and after budding, this process is termed maturation. Proteolytic cleavage of p66 RT removes the RNase H domain to yield the p51 RT subunit. Nucleocapsid protein p7 might be further cleaved after virus entry.
Capsid protein p24 is phosphorylated.
Matrix protein p17 is tyrosine phosphorylated presumably in the virion by a host kinase. This modification targets the matrix protein to the nucleus.

HIV1 p55+p24+p17,艾滋病病毒抗体Similarity:
Contains 2 CCHC-type zinc fingers.
Contains 1 integrase catalytic domain.
Contains 1 integrase-type DNA-binding domain.
Contains 1 integrase-type zinc finger.
Contains 1 peptidase A2 domain.
Contains 1 reverse transcriptase domain.
Contains 1 RNase H domain.

Gene ID:
155030

Database links:
UniProtKB/Swiss-Prot: P04585.4

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.